Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials.
colorectal cancer
doublet chemotherapy
elderly patients
oxaliplatin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Apr 2019
24 Apr 2019
Historique:
received:
26
03
2019
revised:
17
04
2019
accepted:
21
04
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
27
4
2019
Statut:
epublish
Résumé
Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%,
Identifiants
pubmed: 31022922
pii: cancers11040578
doi: 10.3390/cancers11040578
pmc: PMC6521155
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2003 Jun 15;21(12):2268-75
pubmed: 12805325
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
pubmed: 16084735
Oncology. 2005;69(2):122-9
pubmed: 16118508
Expert Rev Anticancer Ther. 2006 May;6(5):795-800
pubmed: 16759169
J Clin Oncol. 2006 Sep 1;24(25):4085-91
pubmed: 16943526
Clin Colorectal Cancer. 2007 Jan;6(5):362-6
pubmed: 17311701
Clin Transl Oncol. 2007 Jun;9(6):392-400
pubmed: 17594954
Cancer. 2007 Oct 1;110(7):1611-20
pubmed: 17705197
Cancer. 2007 Dec 15;110(12):2666-71
pubmed: 17963264
Crit Rev Oncol Hematol. 2008 Sep;67(3):273-8
pubmed: 18595728
Ann Oncol. 2010 Apr;21(4):781-6
pubmed: 19713248
Oncologist. 2010;15(6):584-92
pubmed: 20495217
Lancet. 2011 May 21;377(9779):1749-59
pubmed: 21570111
Clin Colorectal Cancer. 2012 Sep;11(3):200-6
pubmed: 22421001
Cancer. 2013 Feb 15;119(4):722-8
pubmed: 22990939
Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64
pubmed: 23100174
Clin Colorectal Cancer. 2013 Mar;12(1):62-9
pubmed: 23102897
Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
Anticancer Agents Med Chem. 2013 Nov;13(9):1344-53
pubmed: 24102280
Anticancer Res. 2013 Oct;33(10):4627-30
pubmed: 24123040
Ann Oncol. 2015 Mar;26(3):463-76
pubmed: 25015334
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
Clin Colorectal Cancer. 2015 Mar;14(1):52-7
pubmed: 25442812
Curr Oncol. 2014 Dec;21(6):318-28
pubmed: 25489259
Int J Colorectal Dis. 2015 Oct;30(10):1305-10
pubmed: 26099322
BMC Cancer. 2015 Oct 24;15:786
pubmed: 26497654
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Lancet Gastroenterol Hepatol. 2019 May;4(5):331-333
pubmed: 30852135
Cancer. 1994 Oct 1;74(7 Suppl):1995-2003
pubmed: 8087762
Cancer. 1998 Jun 1;82(11):2123-34
pubmed: 9610691